Fractyl Health, Inc. GUTS
0.90 USD -0.08 (-7.89%)
At closeNov 5, 2026, 4:13 PM EST
0.88 -0.02 -1.76%
After hours · Nov 5, 4:13 PM ET
0.8702 Day range 0.9997
0.821 52-week range 29.34
- YTD
- -96.61%
- 1 year
- -93.39%
- Market cap
- 11.88M
- Revenue (ttm)
- 97.00K
- EPS (ttm)
- -10.56
- Shares out
- 48.10M
- Forward P/E
- -0.77
- YTD return
- -96.61%
- 1-year return
- -93.39%
- Volume
- 149.13K
- Avg volume
- 469.80K
- Open
- 0.98
- Previous close
- 0.9725
- Day's range
- 0.8702 – 0.9997
- 52-week range
- 0.821 – 29.34
- Price target
- 15.50 (+1630.3%)
- Earnings date
- Aug 14, 2024
5D -0.0183 (-2.00%)
Key statistics
- Enterprise value
- 64.36M
- PEG ratio
- 0.00
- Price / sales
- 942.14
- Price / book
- 1.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -61.10%
- Free cash flow
- -36.66M
- Total cash
- 84.66M
- Total debt
- 62.93M
- Return on equity
- -286.16%
- Short % of float
- 9.10%
- 50-day average
- 2.37
- 200-day average
- 4.29
Analyst view
Price target (mean) 15.50 +1630.3% upside
Now 0.8958
- Target (low)
- 13.00
- Target (mean)
- 15.50
- Target (high)
- 18.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.435.
Financials — quick view
GUTS Revenue — quarterly 0
GUTS Net income — quarterly -25.54M
GUTS EPS — quarterly -1.92
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.50 | -0.48 | +0.02 | +4.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.46 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.46 | -0.36 | +0.10 | +21.74% |
| May 13, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.30 | -0.75 | -0.45 | -150.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 28, 2024 | Evercore ISI Group | init | — | Outperform |
| Feb 27, 2024 | Morgan Stanley | init | — | Overweight |
About Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fractyl.com
News
Fractyl Health Expands Revita Patent Portfolio Ahead Of Planned FDA De Novo Submission 
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization 
Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance 
Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance 
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance 
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS - Canaccord Genuity Maintains Buy on Fractyl Health, Lowers Price Target to $39
GUTS CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Fractyl (NASDAQ: GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026 
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm 
GUTS DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026
Your note
Sign in to keep a note on GUTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMERICAN HOME ASSURANCE CO | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 5, 2024 | 283,878 |
| AMERICAN INTERNATIONAL GROUP, INC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 5, 2024 | 0 |
| CAPLAN JAY DAVID | President | Sale | Nov 10, 2024 | 631,160 |
| CVF LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 5, 2024 | 0 |
| ELIA MARC | Director | Purchase | Feb 5, 2024 | 0 |
| FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 5, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deer Management Co. LLC | 9.92% | 4,770,901 | 9.06M | Sep 29, 2024 |
| Hcc Manager LLC | 9.72% | 4,673,871 | 8.88M | Sep 29, 2024 |
| Maverick Capital Ltd. | 8.83% | 4,248,492 | 8.07M | Sep 29, 2024 |
| Blackrock Inc. | 4.64% | 2,232,516 | 4.24M | Sep 29, 2024 |
| M28 Capital Management LP | 3.86% | 1,856,117 | 3.53M | Sep 29, 2024 |
| Ensign Peak Advisors, Inc | 2.93% | 1,408,852 | 2.68M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.34% | 646,819 | 1.23M | Oct 30, 2024 |
| MFS New Discovery Fund | 1.33% | 639,147 | 1.21M | Aug 30, 2024 |
| MFS Variable Insurance Trust-MFS New Discovery Series | 0.41% | 195,104 | 370.70K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.40% | 194,797 | 370.11K | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.36% | 171,366 | 325.60K | Oct 30, 2024 |
| Pacific Select Fund-Small Cap Growth Portfolio | 0.30% | 143,198 | 272.08K | Sep 29, 2024 |